Etaracizumab

Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) [1][2][3][4][5].

Product Specifications

CAS Number

[892553-42-3]

Product Name Alternative

LM609; MEDI-522

UNSPSC

12352203

Target

Akt; Apoptosis; Integrin

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Cytoskeleton; PI3K/Akt/mTOR

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/etaracizumab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Etaracizumab]

Molecular Weight

(146.64 kDa)

References & Citations

[1]Hersey P, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha (v) beta (3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15;116 (6) :1526-34.|[2]Joshua P. Reddy, et al, Abstract 6358: Arming tumor-associated macrophages to inhibit cancer progression. Cancer Res 15 March 2024; 84 (6_Supplement) : 6358.|[3]Delbaldo, C., et al., (2008) . Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Investigational new drugs, 26 (1), 35–43.|[4]Landen, C. N., et al., (2008) . Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (New York, N.Y.), 10 (11), 1259–1267.|[5]Borst, A. J., et al., (2017) . The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human αVβ3 Integrin via Steric Hindrance. Structure (London, England : 1993), 25 (11), 1732–1739.e5.